Enrolling patients in clinical trials is increasingly challenging. First the globalization and diversification of clinical trials, then the COVID-19 pandemic and its inherent limitations. In response to these challenges, decentralized clinical trials (DCTs) became a popular alternative to traditional clinical trials.
DCTs augment more regimented, in-person approaches with adaptive, data-driven alternatives. Many now also place increasing emphasis on patient-centered and at-home participation. But just as with typical clinical trials, DCTs present a number of challenges for sponsors. One of the biggest hurdles is the safety and viability of samples collected from and treatments shipped directly to patients.
Learn more about how direct-to- and direct-from-patient shipments differ from larger scale cold chain shipments in our recent white paper.
